Canaloplasty Treatment Market Size, Share, Industry, Forecast and Outlook (2023-2030)

Canaloplasty Treatment Market Overview
The global Canaloplasty Treatment Market is poised to experience significant growth, projecting a high Compound Annual Growth Rate (CAGR) throughout the forecast period from 2023 to 2030.
Canaloplasty is a surgical procedure designed to treat glaucoma, a group of eye conditions characterized by elevated intraocular pressure (IOP). This increased pressure can lead to optic nerve damage and subsequent vision loss. The primary objective of canaloplasty is to reduce IOP by unblocking and widening the eye's natural drainage system. This surgical intervention proves effective in preserving vision and can provide long-lasting IOP reduction, potentially reducing the need for further procedures and medication adjustments.

Request for Free Sample: https://www.datamintelligence.com/download-sample/canaloplasty-treatment-market

Market Dynamics
Strategies Adopted by Companies
The market growth is driven by strategies adopted by companies, including product launches and technological advancements. For example, Nova Eye Medical Limited introduced the iTrack Advance, a next-generation canaloplasty device, demonstrating a commitment to expanding the canaloplasty sector.
Rise in Glaucoma Cases
The global market's revenue growth is attributed to the increasing number of glaucoma cases. Glaucoma is a painless eye ailment that often remains asymptomatic until substantial vision loss occurs. This cyclical increase in glaucoma patients contributes to the market's expansion.
Restraint
While canaloplasty has several positive effects, factors such as the need for skilled surgeons and the associated cost can limit its widespread adoption. The sensitivity of the treatment demands a high level of surgeon competence, and the cost may be a significant influencing factor, particularly in regions with inadequate healthcare coverage.

Segmentation Analysis
The global market is segmented based on type, surgical techniques, end-user, and region. Notably, the microcatheter-assisted canaloplasty segment holds a substantial market share, accounting for approximately 41.7% of canaloplasty treatment.

Microcatheter-Assisted Canaloplasty
Microcatheter-assisted canaloplasty is a minimally invasive procedure that minimizes post-operative discomfort and promotes faster recovery compared to traditional, more invasive glaucoma surgeries. Advancements in microcatheter technology and surgical techniques contribute to the refinement and improvement of outcomes, making it an increasingly viable option.

Geographical Distribution of the Market
North America Dominates the Market
North America is expected to lead in revenue share, accounting for approximately 38.4% in 2022. Factors such as the presence of leading market players, efficient reimbursement policies, and public health programs contribute to the region's growth. Additionally, initiatives like Eye America and the prevalence of glaucoma in the region further boost market demand.

Asia-Pacific Shows Significant Growth
Asia-Pacific is projected to experience significant revenue growth due to improvements in healthcare infrastructure, rising disposable income, and advancements in technology. Government initiatives, healthcare reforms, and the presence of domestic companies contribute to the region's growing demand for glaucoma surgery devices.

COVID-19 Impact Analysis
The initial restrictions and safety concerns led to limited patient access to treatment centres. However, as restrictions eased, there was a noticeable recovery in the market, emphasizing minimally invasive procedures and an increase in telemedicine consultations. Rigorous safety measures were implemented by manufacturers and healthcare providers, stabilizing healthcare systems and restoring patient confidence.

Canaloplasty Treatment Market Companies
Major players in the market include Nova Eye Medical Limited, Ellex Medical Lasers, Haag-Streit, New World Medical, Sight Sciences, Glaukos Corporation, Ophthalmic Instruments Pte Ltd., New World Medical, Inc, Ohio Eye Alliance, iScience Interventional, and others.

Key Developments
In November 10, 2021, Sight Sciences, Inc. received FDA approval for an Investigational Device Exemption (IDE) to conduct a clinical study evaluating the safety and effectiveness of a new, higher-volume OMNI device for canal vasodilation to lower intraocular pressure.

Related Reports:

https://www.datamintelligence.com/download-sample/annuloplasty-rings-market

https://www.datamintelligence.com/download-sample/angioplasty-balloons-market

Media Contact
Company Name: DataM Intelligence
Email: info@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com/

About DataM Intelligence
DataM Intelligence 4Market Research is a Market Research firm that provides end-to-end business solutions to organizations from Research to Consulting. We at DataM Intelligence leverage our top trademark trends, insights, and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of Syndicate Reports & and; Customized Reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries, catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.